Hans Hoffmann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hans Hoffmann has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
Hendrik Dienemann
Department of Thoracic Surgery, Thoraxklinik, Heidelberg University, Heidelberg, Germany
8 shared publicationsThomas Schneider
Department of Thoracic Surgery, St. Vincentius Kliniken, Karlsruhe, Germany; Department of Thoracic Surgery, Thoraxklinik, Heidelberg University, Heidelberg, Germany
7 shared publicationsArne Warth
Institute of Pathology, Heidelberg University, Heidelberg, Germany; Translational Lung Research Center Heidelberg, Heidelberg, Germany
4 shared publicationsPhilipp A. Schnabel
Institute of Pathology, Department of General Pathology, University of Heidelberg, Germany
4 shared publicationsH. Dienemann
Thoraxklinik am Universitätsklinikum, Heidelberg, Deutschland
3 shared publicationsAlexander H. Enk
Department of Dermatology, Heidelberg University, Heidelberg, Germany
2 shared publications
Latest Publications
- Open Access
- 14 December 2017
- Published by Springer Nature in BMC Cancer
- Vol. 17 (1) , 1-9
Shifting cancer care towards Multidisciplinarity: the cancer center certification program of the German cancer society
Over the last decades numerous initiatives have been set up that aim at translating the best available medical knowledge and treatment into clinical practice. The inherent complexity of the programs and discrepancies in the terminology used make it difficult to appreciate each of them distinctly and compare their specific strengths and weaknesses. To allow comparison and stimulate dialogue between different programs, we in this paper provide an overview of the German Cancer Society certification program for multidisciplinary cancer centers that was established in 2003. In the early 2000s the German Cancer Society assessed the available information on quality of cancer care in Germany and concluded that there was a definite need for a comprehensive, transparent and evidence-based system of quality assessment and control. This prompted the development and implementation of a voluntary cancer center certification program that was promoted by scientific societies, health-care providers, and patient advocacy groups and based on guidelines of the highest quality level (S3). The certification system structures the entire process of care from prevention to screening and multidisciplinary treatment of cancer and places multidisciplinary teams at the heart of this program. Within each network of providers, the quality of care is documented using tumor-specific quality indicators. The system started with breast cancer centers in 2003 and colorectal cancer centers in 2006. In 2017, certification systems are established for the majority of cancers. Here we describe the rationale behind the certification program, its history, the development of the certification requirements, the process of data collection, and the certification process as an example for the successful implementation of a voluntary but powerful system to ensure and improve quality of cancer care. Since 2003, over 1 million patients had their primary tumors treated in a certified center. There are now over 1200 sites for different tumor entities in four countries that have been certified in accordance with the program and transparently report their results from multidisciplinary treatment for a substantial proportion of cancers. This led to a fundamental change in the structure of cancer care in Germany and neighboring countries within one decade.
- 14 December 2017
- Published by Springer Nature in BMC Cancer
- Vol. 17 (1) , 1-9
Open AccessShifting cancer care towards Multidisciplinarity: the cancer center certification program of the German cancer society
Over the last decades numerous initiatives have been set up that aim at translating the best available medical knowledge and treatment into clinical practice. The inherent complexity of the programs and discrepancies in the terminology used make it difficult to appreciate each of them distinctly and compare their specific strengths and weaknesses. To allow comparison and stimulate dialogue between different programs, we in this paper provide an overview of the German Cancer Society certification program for multidisciplinary cancer centers that was established in 2003. In the early 2000s the German Cancer Society assessed the available information on quality of cancer care in Germany and concluded that there was a definite need for a comprehensive, transparent and evidence-based system of quality assessment and control. This prompted the development and implementation of a voluntary cancer center certification program that was promoted by scientific societies, health-care providers, and patient advocacy groups and based on guidelines of the highest quality level (S3). The certification system structures the entire process of care from prevention to screening and multidisciplinary treatment of cancer and places multidisciplinary teams at the heart of this program. Within each network of providers, the quality of care is documented using tumor-specific quality indicators. The system started with breast cancer centers in 2003 and colorectal cancer centers in 2006. In 2017, certification systems are established for the majority of cancers. Here we describe the rationale behind the certification program, its history, the development of the certification requirements, the process of data collection, and the certification process as an example for the successful implementation of a voluntary but powerful system to ensure and improve quality of cancer care. Since 2003, over 1 million patients had their primary tumors treated in a certified center. There are now over 1200 sites for different tumor entities in four countries that have been certified in accordance with the program and transparently report their results from multidisciplinary treatment for a substantial proportion of cancers. This led to a fundamental change in the structure of cancer care in Germany and neighboring countries within one decade.
- 1 January 2016
- Published by Elsevier in Seminars in Thoracic and Cardiovascular Surgery
- Vol. 28 (2) , 585-592
Immune Response After Radiofrequency Ablation and Surgical Resection in Nonsmall Cell Lung Cancer
- 1 January 2016
- Published by Elsevier in Seminars in Thoracic and Cardiovascular Surgery
- Vol. 28 (2) , 585-592
Immune Response After Radiofrequency Ablation and Surgical Resection in Nonsmall Cell Lung Cancer
- 1 November 2015
- Published by Elsevier in Lung Cancer
- Vol. 90 (2) , 224-229
The dynamic pattern of recurrence in curatively resected non-small cell lung cancer patients: Experiences at a single institution
- 1 November 2015
- Published by Elsevier in Lung Cancer
- Vol. 90 (2) , 224-229
The dynamic pattern of recurrence in curatively resected non-small cell lung cancer patients: Experiences at a single institution
- 7 December 2013
- Published by Springer Nature in best practice onkologie
- Vol. 8 (6) , 42-51
Pleuramesotheliom
- 7 December 2013
- Published by Springer Nature in best practice onkologie
- Vol. 8 (6) , 42-51
Pleuramesotheliom
- 1 April 2013
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 95 (4) , 1180
Invited Commentary
- 1 April 2013
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 95 (4) , 1180
Invited Commentary
- 1 July 2011
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 6 (7) , 1162-1168
Non-small Cell Lung Cancer Induces an Immunosuppressive Phenotype of Dendritic Cells in Tumor Microenvironment by Upregulating B7-H3
- 1 July 2011
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 6 (7) , 1162-1168
Non-small Cell Lung Cancer Induces an Immunosuppressive Phenotype of Dendritic Cells in Tumor Microenvironment by Upregulating B7-H3
- 1 June 2011
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 39 (6) , 968-973
The efficacy of bipolar and multipolar radiofrequency ablation of lung neoplasms — results of an ablate and resect study
Radiofrequency ablation (RFA) has obtained increasing attention as an interventional approach for the local treatment of primary and secondary lung neoplasms. The local effect of the procedure is usually controlled by radiologic means. The objectives of this 'ablate and resect' study were to investigate the efficacy of bipolar and multipolar RFA by histologic evaluation and to compare the two techniques. In a total of 32 subjects with histologically proven non-small-cell lung cancer or pulmonary metastases from an extrathoracic primary tumor, bipolar, or multipolar RFA was performed during open thoracotomy. Curative resection (lobectomy or wedge resection including mediastinal lymph node dissection) was performed subsequently. The extent of cell death and early histologic findings following RFA were determined by histology and immunohistochemistry (nicotinamide adenine dinucleotide (NADH) and monoclonal anti-mitochondrial antibodies MAB 1273). Intra-operative bipolar and multipolar RFA is a safe procedure, and there was no bleeding or thermal damage of the lung tissue. Routine histologic staining could not identify tumor cell death. However, immunohistochemistry was able to verify cell death in the ablated tumor tissue. Complete tumor cell necrosis was determined in 12 tumors (37.5%); and scattered vital tumor tissue was detected in 16 tumors (50%). Incomplete ablation with a ratio of >20% vital tumor tissue was found in four tumors (12.5%), particularly surrounding vascular structures within the tumor tissue or in marginal zones of the tumor tissue. The local efficacy of bipolar and multipolar RFA was comparable, and incomplete ablations were found only in adenocarcinoma. Bipolar and multipolar RFA in an open thoracotomy setting is a technically feasible and safe procedure. Early immunohistochemical findings after RFA showed complete tumor cell necrosis in 38% of cases. The high rate of viable tumor cells remaining after ablation casts doubt on RFA as a curative concept. This approach should be reserved for palliative indications. Patients fulfilling the criteria for curative resection should not be denied surgery.
- 1 June 2011
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 39 (6) , 968-973
The efficacy of bipolar and multipolar radiofrequency ablation of lung neoplasms — results of an ablate and resect study
Radiofrequency ablation (RFA) has obtained increasing attention as an interventional approach for the local treatment of primary and secondary lung neoplasms. The local effect of the procedure is usually controlled by radiologic means. The objectives of this 'ablate and resect' study were to investigate the efficacy of bipolar and multipolar RFA by histologic evaluation and to compare the two techniques. In a total of 32 subjects with histologically proven non-small-cell lung cancer or pulmonary metastases from an extrathoracic primary tumor, bipolar, or multipolar RFA was performed during open thoracotomy. Curative resection (lobectomy or wedge resection including mediastinal lymph node dissection) was performed subsequently. The extent of cell death and early histologic findings following RFA were determined by histology and immunohistochemistry (nicotinamide adenine dinucleotide (NADH) and monoclonal anti-mitochondrial antibodies MAB 1273). Intra-operative bipolar and multipolar RFA is a safe procedure, and there was no bleeding or thermal damage of the lung tissue. Routine histologic staining could not identify tumor cell death. However, immunohistochemistry was able to verify cell death in the ablated tumor tissue. Complete tumor cell necrosis was determined in 12 tumors (37.5%); and scattered vital tumor tissue was detected in 16 tumors (50%). Incomplete ablation with a ratio of >20% vital tumor tissue was found in four tumors (12.5%), particularly surrounding vascular structures within the tumor tissue or in marginal zones of the tumor tissue. The local efficacy of bipolar and multipolar RFA was comparable, and incomplete ablations were found only in adenocarcinoma. Bipolar and multipolar RFA in an open thoracotomy setting is a technically feasible and safe procedure. Early immunohistochemical findings after RFA showed complete tumor cell necrosis in 38% of cases. The high rate of viable tumor cells remaining after ablation casts doubt on RFA as a curative concept. This approach should be reserved for palliative indications. Patients fulfilling the criteria for curative resection should not be denied surgery.
- 1 March 2011
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 6 (3) , 432-438
Foxp3+ Regulatory T Cells and Natural Killer Cells Distinctly Infiltrate Primary Tumors and Draining Lymph Nodes in Pulmonary Adenocarcinoma
- 1 March 2011
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 6 (3) , 432-438
Foxp3+ Regulatory T Cells and Natural Killer Cells Distinctly Infiltrate Primary Tumors and Draining Lymph Nodes in Pulmonary Adenocarcinoma
- Open Access
- 1 August 2010
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 5 (8) , 1206-1212
A Pragmatic Approach to the Diagnosis of Nodal Micrometastases in Early Stage Non-small Cell Lung Cancer
- 1 August 2010
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 5 (8) , 1206-1212
Open AccessA Pragmatic Approach to the Diagnosis of Nodal Micrometastases in Early Stage Non-small Cell Lung Cancer
- 31 December 2009
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 88 (6) , 1736
Invited Commentary
- 31 December 2009
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 88 (6) , 1736
Invited Commentary